PMC9253383_01
(A) Blood exams, nasopharyngeal (NF) culture result, and SpO2 during the episodes; (B) lung CT scan performed at different time points; (C) timeline; and (D) real-time PCR cycle threshold (Ct) of SARS-CoV-2 on nasal swab.
fimmu-13-891274-g001.jpg
PMC9253383_01_fimmu-13-891274-g001.jpg
f1
The positivity was confirmed on January 18, 2021, by RT-PCR on an NS ( Figure 1 ). Subsequent RT-PCR performed on NS documented the asymptomatic infection persistence ( Figure 1 ) until mid-March when he presented low-grade fever, dry cough, chest pain, and exertional dyspnea associated with a worsening of pulmonary consolidation. Unfortunately, it had a low impact on viral replication as documented by low cycle threshold (Ct) values in RT-PCR performed on the NS ( Figure 1 ) and viral load quantification ranging from 103 to 105 cp/ml (ORF8 and RdRp genes). CT scan performed on April 10 showed almost complete remission of pulmonary consolidation. Considering the persistence of high viral load in NS ( Figure 1 ) on April 23, he was treated with SARS-CoV-2-neutralizing monoclonal antibodies REGEN-COV (casirivimab and imdevimab) with good tolerability and efficacy. April 30 and May 12 turned negative ( Figure 1 ). According to epidemiology tracking, SARS-CoV-2 strain circulation at the time was mostly represented by the wild-type lineage, the Alpha (B.1.1.7 VOC-202012/01 genomes),
PMC9253383_02